Article

Estimating the Financial Impact of Gene Therapy*

2020-10-31

Abstract excerpt

We assess the potential financial impact of future gene therapies by identifying the 109 late-stage gene therapy clinical trials currently underway, estimating the prevalence and incidence of their corresponding diseases, developing novel mathematical models of the increase in quality-adjusted life years for each approved gene therapy, and simulating the launch prices and the expected spending of these therapies o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f2da3969-a98c-52a6-8a3d-2de818a9b676
DOI: 10.1101/2020.10.27.20220871

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Estimating the Financial Impact of Gene Therapy*DOI 10.1101/2020.10.27.20220871Read

The estimated annual financial impact of gene therapy in the United StatesSemantic proximity Read

Gene therapies development: slow progress and promising prospectSemantic proximity Read

Gene therapy in hemophilia A: a cost-effectiveness analysisSemantic proximity Read

Patient, consumer and societal values, perceptions and preferences on high-cost gene therapiesSemantic proximity Read

The translational gap for gene therapies in low- and middle-income countriesSemantic proximity Read

Quantifying the potential for future gene therapy to lower lifetime risk of polygenic late-onset diseasesSemantic proximity Read

Financing translation: Analysis of the NCATS rare-diseases portfolioSemantic proximity Read

The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspectiveSemantic proximity Read

The Amortization of Funding Gene Therapies: Making the “Intangibles” Tangible for PatientsSemantic proximity Read

Planning for progress: A US regulatory approach to advancing the clinical development of gene therapiesSemantic proximity Read

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United StatesSemantic proximity Read

Value-based genomic screening: exploring genomic screening for chronic diseases using triple value principles.Semantic proximity Read